drugset
drugset / Trial / NCT00492037

Study of Efficacy & Safety of Oral YM087 in Subjects With Euvolemic or Hypervolemic Hyponatremia

NCT00492037 ↗

Phase 3 Completed 83 enrolled Cumberland Pharmaceuticals Parke-Davis · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

Study of efficacy \& safety of oral YM087 in subjects with euvolemic or hypervolemic hyponatremia

Timeline

Start
2000-01
Primary completion
—
Completion
2002-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Conivaptan Small molecule — Oral

Indications

No indication recorded.